Peer Review reports
From: Tumour inhibitory activity on pancreatic cancer by bispecific nanobody targeting PD-L1 and CXCR4
| Original Submission | ||
|---|---|---|
| 26 Apr 2022 | Submitted | Original manuscript |
| 27 Jun 2022 | Reviewed | Reviewer Report |
| 8 Aug 2022 | Reviewed | Reviewer Report - Patricia Gaule |
| 1 Sep 2022 | Author responded | Author comments - Mingyuan Wu |
| Resubmission - Version 2 | ||
| 1 Sep 2022 | Submitted | Manuscript version 2 |
| 15 Sep 2022 | Author responded | Author comments - Mingyuan Wu |
| Resubmission - Version 3 | ||
| 15 Sep 2022 | Submitted | Manuscript version 3 |
| 29 Sep 2022 | Reviewed | Reviewer Report |
| Resubmission - Version 4 | ||
| Submitted | Manuscript version 4 | |
| Publishing | ||
| 4 Oct 2022 | Editorially accepted | |
| 25 Oct 2022 | Article published | 10.1186/s12885-022-10165-7 |
You can find further information about peer review here.